Geode Capital Management LLC Has $3.03 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Geode Capital Management LLC boosted its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 5.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,391,702 shares of the company’s stock after acquiring an additional 77,350 shares during the quarter. Geode Capital Management LLC owned 1.97% of Ventyx Biosciences worth $3,034,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences during the third quarter worth approximately $26,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the period. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences during the 3rd quarter valued at $42,000. The Manufacturers Life Insurance Company increased its stake in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after acquiring an additional 7,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ventyx Biosciences in the second quarter worth $58,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, Director Sheila Gujrathi purchased 130,000 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now directly owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John Nuss sold 13,161 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the sale, the insider now directly owns 485,701 shares of the company’s stock, valued at $1,097,684.26. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 630,000 shares of company stock worth $1,262,415. 18.18% of the stock is owned by corporate insiders.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock opened at $2.42 on Tuesday. Ventyx Biosciences, Inc. has a one year low of $1.67 and a one year high of $11.48. The company’s fifty day moving average price is $2.29 and its two-hundred day moving average price is $2.29. The company has a market capitalization of $171.12 million, a price-to-earnings ratio of -1.03 and a beta of 0.55.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VTYX shares. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a research report on Monday, November 11th. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.